J&J’s Aciphex Feels The Burn As Rx PPI Market Growth Levels Off
This article was originally published in The Tan Sheet
Domestic sales of Johnson & Johnson's Rx proton pump inhibitor Aciphex (rabeprazole 20 mg) were negatively affected by the launch of Procter & Gamble's Prilosec OTC, providing another example of the sluggish growth of the prescription PPI market
You may also be interested in...
Consumer spending on prescription non-steroidal anti-inflammatories and antihistamines decreased 45% and 44%, respectively, when insurance copays for the products doubled, according to a study published in the Journal of the American Medical Association May 19
Johnson & Johnson cleared its final regulatory hurdle toward the acquisition of Merck's stake in the nonprescription drug joint venture following European Commission approval, announced March 30
Abbott Labs plans to counter the launch of Prilosec OTC with a broad direct-to-consumer advertising campaign for its Rx proton pump inhibitor Prevacid